Biomarkers for hepatocellular carcinoma based on body fluids and feces  

作　　者：Ming-Cheng Guan Wei Ouyang Ming-Da Wang Lei Liang Na Li Ting-Ting Fu Feng Shen Wan-Yee Lau Qiu-Ran Xu Dong-Sheng Huang Hong Zhu Tian Yang 

机构地区：[1]Department of Medical Oncology,The First Affiliated Hospital of Soochow University,Suzhou 215006,Jiangsu Province,China [2]Department of Hepatobiliary Surgery,Eastern Hepatobiliary Surgery Hospital(Navy Medical University),Second Military Medical University,Shanghai 200438,China

出　　处：《World Journal of Gastrointestinal Oncology》2021年第5期351-365,共15页世界胃肠肿瘤学杂志（英文版）（电子版）

基　　金：Supported by National Natural Science Foundation of China,No.81972726,No.81871949 and No.81572345.

摘　　要：Novel non-/minimally-invasive and effective approaches are urgently needed to supplement and improve current strategies for diagnosis and management of hepatocellular carcinoma(HCC).Overwhelming evidence from published studies on HCC has documented that multiple molecular biomarkers detected in body fluids and feces can be utilized in early-diagnosis,predicting responses to specific therapies,evaluating prognosis before or after therapy,as well as serving as novel therapeutic targets.Detection and analysis of proteins,metabolites,circulating nucleic acids,circulating tumor cells,and extracellular vesicles in body fluids(e.g.,blood and urine)and gut microbiota(e.g.,in feces)have excellent capabilities to improve different aspects of management of HCC.Numerous studies have been devoted in identifying more promising candidate biomarkers and therapeutic targets for diagnosis,treatment,and monitoring responses of HCC to conventional therapies,most of which may improve diagnosis and management of HCC in the future.This review aimed to summarize recent advances in utilizing these biomarkers in HCC and discuss their clinical significance.

关 键 词：Hepatocellular carcinoma BIOMARKER BLOOD URINE FECES Gut microbiota 

分 类 号：R735.7[医药卫生—肿瘤]